NOCIL Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Published 3 Aug 2026 | Chemicals & Petrochemicals | Market Cap: ₹2.7K Cr

Domestic volumes showed high single-digit growth in Q3 FY '26, driven by improved demand (GST 2.0). - Overall volume growth for FY '26 is expected at 3%-4%, despite a 5% degrowth in H1 FY '26. - Export volumes faced temporary decline due to seasonal effects and U.S. Volume Growth: Expected 3-4% volume growth for FY '26 despite H1 degrowth; high single-digit domestic volume growth in Q3 FY '26; double-digit export volume growth anticipated for FY '27.

From NOCIL Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹167

Market Cap

₹2.7K Cr

P/E Ratio

38.8

How does NOCIL Ltd rank in Chemicals & Petrochemicals?

Compare NOCIL Ltd against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

NOCIL Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹330 Cr, net profit ₹17 Cr.

Full financials →

📊 Revenue & Sales Performance

→Domestic volumes showed high single-digit growth in Q3 FY '26, driven by improved demand (GST 2.0).
→Overall volume growth for FY '26 is expected at 3%-4%, despite a 5% degrowth in H1 FY '26.
→Export volumes faced temporary decline due to seasonal effects and U.S. tariffs but expected to recover with revised U.S. tariff structures.
→Double-digit volume growth is anticipated in FY '27, primarily from base capacity ramp-up; contributions from new TDQ capacity will be moderate initially.
→Newer products are expected to contribute 10%-12% of overall volumes once commercialized.
→India-EU FTA and U.S. trade agreements likely to bolster export opportunities from FY '27 onward.
→Operational efficiencies and volume growth expected to enhance margins and revenue growth in medium term.

📈 Profitability & Margins

→Volume Growth: Expected 3-4% volume growth for FY '26 despite H1 degrowth; high single-digit domestic volume growth in Q3 FY '26; double-digit export volume growth anticipated for FY '27.
→Revenue: FY '26 revenue impacted by competitive pricing/dumping but volume growth and operational efficiencies expected to aid margins.
→EBITDA Margin: Targeting operating EBITDA margin improvement of 150 basis points annually over the next 2-4 years through cost initiatives and higher utilization post-expansion.
→Profitability: PBT and PAT for 9 months FY '26 declined compared to prior year due to tax changes and volume/price pressures; improvement expected driven by export ramp-up and domestic demand.
→New Capacity: TDQ capacity ramp-up and product approvals expected to contribute moderately to FY '27 volumes, accelerating in FY '28-FY '29.
→Cost Savings: Ongoing cost initiatives during FY '26 have already generated savings (~Rs.23 crores), with more to come for margin expansion.
→Market Opportunities: Growth aided by India-US and India-EU FTAs, leading to volume gains in multiple geographies.

See what NOCIL Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→NOCIL is expanding its antioxidant capacity with the new TDQ facility at Dahej, expected to increase overall capacity by about 20%.
→Production trials for the TDQ facility are planned during the first half of calendar year 2026, with a slower ramp-up in FY '27 and faster growth expected in FY '28 and FY '29 after approvals.
→The company anticipates that the new products in the pipeline, including those related to TDQ, will contribute around 10-12% of the current volume once commercialized and ramped up.
→Operational efficiency initiatives and cost-saving measures are ongoing, aimed at improving margins and supporting growth.
→While no other specific new strategic investments are detailed, NOCIL continues efforts in innovation and capacity utilization improvements.

💰 Fundraising & Capital Structure

→The transcript does not mention any current or planned fundraising through debt or equity.
→There is no discussion about raising capital via new debt issues or equity offerings.
→The focus is on operational performance, volume growth, cost-saving initiatives, and capacity expansions.
→The company discusses expansions (e.g., TDQ antioxidant facility) funded through internal means.
→No indication of external financing or capital raising plans was shared during the call.

See what NOCIL Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

The transcript and document do not provide specific details on NOCIL Limited's current or expected order book or pending orders. However, from the discussion, the following points are noted that might indirectly relate to future demand and order intake: - FY '27 is expected to see growth in volumes, both domestically and internationally, supported by trade agreements with the U.S. and EU. - Export volume growth is anticipated to return to double digits in FY '27 after some decline in FY '26. - The ramp-up of new TDQ capacity and approvals for new products are expected to contribute to growth in upcoming years. - Domestic volumes showed a high single-digit growth trend in Q3 FY '26. No explicit data on order book size or pending orders was disclosed in the call or filing.

Key Metrics

What NOCIL's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Clean Science & Technology Ltd (Q3 FY26)
Trade deal with Europe starting in FY '27 to potentially reduce tariffs (5.5%-12%), helping competitiveness against China. Key concall takeaways from Clean…
Aether Industries Ltd (Q3 FY26)
The company currently services Baker Hughes with 8 products in commercial production (Site 4) generating a run rate of INR 60 crores this quarter. Key concall…
Kesar Petroprod. (Q3 FY26)
Export markets constitute about 40% of sales, served through 7-8 distributors across geographies. Key concall takeaways from Kesar Petroprod.'s Q3 FY26…
Tata Chemicals (Q3 FY26)
Indian salt capacity expansion of 210 KT per annum with INR 515 crore investment is underway to meet growing demand. Key concall takeaways from Tata…

Compare:vs Pidilite Inds.vs SRF vs Linde India Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were NOCIL Ltd Q3 FY26 results?

What is NOCIL Ltd share price analysis?

NOCIL Ltd currently shows a neutral. The stock trades at a P/E of 38.8 with a market cap of ₹2,696 Cr. Investors should review the full earnings analysis for detailed insights.

Is NOCIL Ltd planning capital expenditure?

NOCIL is expanding its antioxidant capacity with the new TDQ facility at Dahej, expected to increase overall capacity by about 20%.

Keep NOCIL Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.